Viacyte

Main focus: Stem cell engineering for treatment of diabetes

Company stage: Clinical

Diseases: Type 1 and 2 diabetes

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: San Diego, CA, USA

Website: https://viacyte.com/

Pipeline: https://viacyte.com/pipeline/

Partners: CRISPR Therapeutics

Viacyte is developing engineered stem cells in order to treat diabetes. The company has an ongoing collaboration with CRISPR Therapeutics, for which the companies seek to develop a next generation stem cell product for all type 1 diabetes and insulin-requiring type 2 diabetes patients. The programme is currently in a research phase.

ViaCyte, Inc.

Your Latest CMN News

Breaking: CRISPR screen identifies endosomal...

CMN Special

Jun. 30, 2025

A comprehensive CRISPR-CAS whole-genome screen has revealed key proteins controlling anti-sense oligonucleotide (ASO) activity, with a particular...

CMN Weekly (27 June 2025) - Your Weekly CRISPR...

CMN Weekly

Jun. 27, 2025

Some of the best links we picked up around the internet

Tamoxifen controls gene activation with CRISPRa/i

CMN Briefs

Jun. 26, 2025

A tamoxifen-inducible CRISPRa/i system has been developed to enable reversible and rapid control of gene expression in mammalian cells. The platform...

Silent mutations alter cell fitness in humans, PE...

CMN Briefs

Jun. 24, 2025

A high-throughput prime editing screen in human cells reveals that some synonymous mutations, long considered functionally neutral, can significantly...

CMN Weekly (20 June 2025) - Your Weekly CRISPR...

CMN Weekly

Jun. 20, 2025

Some of the best links we picked up around the internet

Intellia Reports Positive Three-Year Follow-up...

CMN Clinical

Jun. 18, 2025

Intellia Therapeutics has reported positive three-year follow-data from the ongoing Phase 1/2 trial of lonvo-z (formerly known as NTLA-2002) in...